Immunovant (IMVT) Liabilities and Shareholders Equity (2018 - 2026)
Immunovant (IMVT) recorded Liabilities and Shareholders Equity of $852.49 million in fiscal Q1 2027 (quarter ended Jun 30, 2026), up 28.9% from $661.44 million a year earlier but down 10.9% from the prior quarter.
Powered by 
Analysis
Immunovant (IMVT) Liabilities and Shareholders Equity (2018 - 2026) Analysis & Trends
At the end of FY2026 (ended Mar 31, 2026), Immunovant reported Liabilities and Shareholders Equity of $957.01 million, up 23.3% from FY2025.
- Annual Liabilities and Shareholders Equity has increased for three straight fiscal years, with a five-year compound annual growth rate of 18.3% (FY2021 to FY2026).
- Across earlier fiscal years, Liabilities and Shareholders Equity came in at $776.22 million in FY2025 (+16.5%), $666.37 million in FY2024 (+64.2%), $405.84 million in FY2023 (-21.3%) and $515.56 million in FY2022 (+25.0%).
- Quarterly Liabilities and Shareholders Equity has ranged from $292.07 million in fiscal Q2 2024 to $1.05 billion in fiscal Q3 2026 over the past five years.
- On a year-over-year basis, Liabilities and Shareholders Equity has increased for six consecutive quarters, with growth averaging 35.0% over the last eight quarters.
- Peak year-over-year performance for Liabilities and Shareholders Equity in the last five years was growth of 150.0% in fiscal Q3 2026, against a decline of 40.8% in fiscal Q3 2025 at the low end.
- Per Business Quant, the preceding three fiscal quarters came in at $957.01 million (Q4 2026), $1.05 billion (Q3 2026) and $582.96 million (Q2 2026).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 638.12 Bn | 556.64 Bn | 17.26 Bn | 201.06 Bn |
| 2 | AbbVie | 462.60 Bn | 435.75 Bn | 12.70 Bn | 135.12 Bn |
| 3 | Merck | 358.70 Bn | 313.13 Bn | 12.21 Bn | 129.80 Bn |
| 4 | Novartis Ag | 272.16 Bn | 228.03 Bn | 11.24 Bn | 122.03 Bn |
| 5 | Astrazeneca | 250.36 Bn | 223.92 Bn | 12.86 Bn | 115.83 Bn |
| 6 | Amgen | 227.87 Bn | 183.27 Bn | 7.24 Bn | 95.64 Bn |
| 7 | Gilead Sciences | 184.97 Bn | 159.08 Bn | 6.22 Bn | 49.36 Bn |
| 8 | Pfizer | 162.61 Bn | 109.56 Bn | 10.94 Bn | 201.13 Bn |
| 9 | Vertex Pharmaceuticals | 132.45 Bn | 104.46 Bn | 2.84 Bn | 27.42 Bn |
| 10 | Immunovant | 6.97 Bn | 6.97 Bn | - | 852.49 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 852.49 Mn |
| Mar 31, 2026 | 957.01 Mn |
| Dec 31, 2025 | 1.05 Bn |
| Sep 30, 2025 | 582.96 Mn |
| Jun 30, 2025 | 661.44 Mn |
| Mar 31, 2025 | 776.22 Mn |
| Dec 31, 2024 | 420.93 Mn |
| Sep 30, 2024 | 515.71 Mn |
| Jun 30, 2024 | 589.68 Mn |
| Mar 31, 2024 | 666.37 Mn |
| Dec 31, 2023 | 711.45 Mn |
| Sep 30, 2023 | 292.07 Mn |
| Jun 30, 2023 | 351.22 Mn |
| Mar 31, 2023 | 405.84 Mn |
| Dec 31, 2022 | 456.24 Mn |
| Sep 30, 2022 | 428.15 Mn |
| Jun 30, 2022 | 458.66 Mn |
| Mar 31, 2022 | 515.56 Mn |
| Dec 31, 2021 | 543.18 Mn |
| Sep 30, 2021 | 566.73 Mn |
API Access
Immunovant Liabilities and Shareholders Equity API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=liabilities-and-shareholders-equity&ticker=IMVT&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "liabilities-and-shareholders-equity", "ticker": "IMVT", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=liabilities-and-shareholders-equity&ticker=IMVT&period=max&api_key=YOUR_API_KEY");
const data = await res.json();